Recent changes
- Oct 9, 2026Oct 9, 2026TRex Bio Prices IPO At $14, Raises $116.7M Pulse story
- Sep 21, 2026Sep 21, 2026TRex Bio, Retension File S-1s For Nasdaq IPOs Pulse story
- Sep 18, 2026Sep 18, 2026IPO an undisclosed amount Fierce Biotech
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Sep 18, 2026 | ipo | — | — | Fierce Biotech |
Investors
Latest Pulse
- Oct 9, 2026TRex Bio Prices IPO At $14, Raises $116.7MTRex Bio priced its IPO at $14.00 per share, the low end of its range, selling 8.33 million shares for about $116.7 million before trading began on Nasdaq as TRXB.→
- Oct 7, 2026Retension Pharmaceuticals Amends S-1 AgainRetension Pharmaceuticals filed a second S-1/A amendment on Oct. 7, two days after its first amendment, continuing to move its IPO registration through SEC review since Pulse first covered its original filing in September.→
- Sep 22, 2026Why Some Fall IPOs Are Filing While Others Are PricingThis fall's IPO pipeline is splitting between companies actually pricing and trading -- newcleo, Electra Therapeutics -- and a growing backlog of filed-but-not-priced names including Nscale and Wella, some sitting for weeks without terms.→
- Sep 21, 2026The Fall 2026 IPO Pipeline Just Got More CrowdedAnthropic's IPO slid a second time to November as ADARx priced at a $1.74 billion target and two more biotechs filed to go public, showing this fall's IPO pipeline growing in volume even as its biggest name keeps slipping.→
- Sep 21, 2026TRex Bio, Retension File S-1s For Nasdaq IPOsTRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.→
Coverage Timeline
newest firstAll Coverage
Related Companies
TRex Bio FAQ
Who are TRex Bio's investors?
TRex Bio's investors include Eli Lilly.
Sources & methodologyshow
Where these figures come from
- Fierce Biotechmajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.